Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of SBRT plus pembrolizumab with or without intratumoral avelumab + ipilimumab + myeloid dendritic cells in NSCLC
2019-003668-32Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, avelumab and ipilimumab in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (2 arms), sponsored by UZ Brussel. Primary endpoints: 1-year progression-free survival rate and Adverse events. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2019-003668-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003668-32.